HCCI’s recent report on rising insulin prices was cited in support of congressional inquiries into drug pricing. This included a letter from U.S. Senator Tim Kaine (D-VA) to executives at Eli Lilly, Novo Nordisk, and Sanofi requesting information on insulin pricing.
Additionally, HCCI’s research on emergency care was cited in a letter from U.S. Senators Bill Cassidy (R-LA) and Todd Young (R-IN) to a number of insurers, employer, and providers discussing surprise billing.
